A Kent and Medway Cancer Network (KMCN) audit of first-line treatment with cisplatin/pemetrexed (CisPem) in non squamous non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Letsa, I. [1 ]
Mikropoulos, C. [1 ]
Burcombe, R. [1 ]
Visioli, A. [1 ]
Sevitt, T. [1 ]
Cominos, M. [1 ]
Beesley, S. [1 ]
机构：
[1] Maidstone Hlth Author, Kent Oncol Ctr, Maidstone, Kent, England
来源：
LUNG CANCER | 2011年 / 71卷
关键词：
D O I：
10.1016/S0169-5002(11)70019-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
19
引用
收藏
页码：S7 / S7
页数：1
相关论文
共 50 条
  • [21] A Better Real World Practice for Pemetrexed in First-Line Treatment of Advanced Mon-Squamous Non-Small Cell Lung Cancer
    Zhang, Y.
    Yan, B.
    Yang, H.
    Yang, N.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S627 - S627
  • [22] Vinorelbine, ifosfamide and cisplatin as first-line treatment in patients with inoperable non-small cell lung cancer
    Montalar, J
    Morales, S
    Maestu, I
    Camps, C
    Vadell, C
    García, R
    Yuste, AL
    Torregrosa, D
    Segura, A
    LUNG CANCER, 2001, 34 (02) : 305 - 311
  • [23] Cisplatin plus docetaxel combination in the first-line treatment of metastatic non-small cell lung cancer
    Kaya, Ali Osman
    Buyukberber, Suleyman
    Dane, Faysal
    Isikdogan, Abdurrahman
    Ustaalioglu, Basak Oven
    Coskun, Ugur
    Yumuk, Perran Fulden
    Dogu, Gamze Gokoz
    Ozdemir, Nuriye Yildirim
    Sevinc, Alper
    Gumus, Mahmut
    Ozkan, Metin
    Yildiz, Ramazan
    Ozturk, Banu
    Yaman, Emel
    Benekli, Mustafa
    TUMORI JOURNAL, 2010, 96 (03): : 400 - 404
  • [24] Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer
    Wu, Yi-Long
    Lu, Shun
    Cheng, Ying
    Zhou, Caicun
    Wang, Mengzhao
    Qin, Shukui
    Lu, You
    Zhang, Yang
    Zhu, Yunzhong
    Song, Xiangqun
    Wang, Xin
    Barraclough, Helen
    Zhang, Xiaoqing
    Chi, Haidong
    Orlando, Mauro
    LUNG CANCER, 2014, 85 (03) : 401 - 407
  • [25] Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancer
    Mir, Olivier
    Boudou-Rouquette, Pascaline
    Giroux, Julie
    Chapron, Jeanne
    Alexandre, Jerome
    Gibault, Laure
    Ropert, Stanislas
    Coriat, Romain
    Durand, Jean-Philippe
    Burgel, Pierre-Regis
    Dusser, Daniel
    Goldwasser, Francois
    LUNG CANCER, 2012, 77 (01) : 104 - 109
  • [26] PALLIATIVE RADIATION DURING PEMETREXED PLUS CISPLATIN FIRST-LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): PATIENT SAFETY IN THE JMDB AND PARAMOUNT TRIALS
    Scagliotti, G. V.
    Gridelli, C.
    de Marinis, F.
    Biesma, B.
    Reck, M.
    San Antonio, B.
    Zimmermann, A. H.
    Visseren-Grul, C.
    Chouaki, N.
    Paz-Ares, L.
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (04) : S45 - S45
  • [27] Phase II study of bevacizumab in combination with cisplatin and docetaxel as first-line treatment of patients (p) with metastatic non-squamous non-small cell lung cancer (NSCLC)
    Ferrer, N.
    Cobo, M.
    Paredes, A.
    Mendez, M.
    Munoz-Langa, J.
    Rueda, A.
    de Mon, M. Alvarez
    Sanchez-Hernandez, A.
    Gallego, R.
    Torrego, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [28] First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the Elderly
    Losanno, Tania
    Gridelli, Cesare
    CURRENT ONCOLOGY REPORTS, 2021, 23 (10)
  • [29] Bevacizumab as first-line treatment for advanced non-small cell lung cancer
    Socinski, Mark A.
    DRUGS OF TODAY, 2008, 44 (04) : 293 - 301
  • [30] First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the Elderly
    Tania Losanno
    Cesare Gridelli
    Current Oncology Reports, 2021, 23
12345